logo
Bright Streak Appears Over US During Aurora Storm, Mystifying Skywatchers

Bright Streak Appears Over US During Aurora Storm, Mystifying Skywatchers

Yahoo20-05-2025

On the night of Saturday 17 May, skywatchers across the US as far south as New Mexico were treated to a peculiar sight: a brilliant stream of whitish light, stretching across the sky.
That was a night for auroral activity, as Earth's magnetic field was buffeted by an influx of particles ejected from the Sun several days earlier. Initially, explanations favored STEVE, the name given to the white-mauve streaks of light emitted by rivers of charged particles flowing through Earth's ionosphere.
STEVE is not an aurora, but, like the auroral displays it often appears alongside, is also a product of space weather.
Spoiler though: the light was not actually STEVE, but a rocket stage dumping out methalox rocket fuel at an altitude of about 250 kilometers (155 miles), bang in the ionosphere, according to astronomer Jonathan McDowell, who tracks activity in Earth space.
At 04:12 UTC, Beijing-based startup LandSpace Technology launched its new Zhuque-2E Y2 methane-fueled carrier rocket, bearing six satellites into Earth orbit. About an hour later, the bright stripe appeared in the sky – not far from midnight over much of the US. That stripe, according to McDowell, was the result of a fuel dump from the rocket's upper stage.
Rocket fuel made from methane and liquid oxygen, known as methalox, is a relatively recent development; LandSpace was the first company to successfully launch a methalox rocket, back in 2023, and this is the fifth flight for its Zhuque-2 series, the company said in a statement.
Methalox is attractive to the aerospace industry because it is cheaper, cleaner, and easier to store, and it may be able to be produced on Mars. That would make crewed missions to the red planet more efficient, since the spacecraft would not need to carry the fuel for the return journey from the outset.
Rocket fuel can glow in the upper atmosphere through several mechanisms. One, seen close to twilight hours, is the illumination of ice particles by the light of the Sun. Closer to midnight, the Sun would be too far around the other side of Earth to be able to illuminate particles, even those high in the atmosphere.
In the ionosphere, molecules involving carbon, hydrogen, and oxygen can generate chemical reactions that produce light. Carbon and hydrogen are the components of methane.
"The reactions [of rocket fuel] with the plasma in the ionosphere include ion-molecule charge exchange, electron-ion recombination, and optical emissions from chemiluminescence," a team of physicists led by Paul Bernhardt of the US Naval Research Laboratory explained in a 2012 paper.
"If the plume is fired into the ionosphere at night, chemiluminescent reactions with ion-molecule charge exchange followed by electron-ion dissociative recombination yield a long-lived glow that can be observed from ground or space."
Anybody know what this light could be? byu/Ambitious_Amount_357 inAstronomy
Usually, the glowing fuel of a rocket blasting into space manifests as a strange spiral in the sky. Rocket fuel masquerading as STEVE is a new experience, but it sure is pretty.
Methalox is gaining traction, with more rocket companies investigating its use. Perhaps more such streaks will appear in the sky. If you see one, now you might know what you're looking at.
TRAPPIST-1 Planets Could Be Swimming in Water, Study Shows
Unknown Species of Bacteria Discovered in China's Space Station
NASA Mission Captures Eerie New View of The Moon And Sun

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca, Daiichi announce results from three trials on DATROWAY
AstraZeneca, Daiichi announce results from three trials on DATROWAY

Business Insider

time5 hours ago

  • Business Insider

AstraZeneca, Daiichi announce results from three trials on DATROWAY

Results from three trials continue to demonstrate the potential of DATROWAY in combination with various immunotherapies to improve outcomes in patients with non-small cell lung cancer, NSCLC, across multiple stages of the disease. These results from TROPION-Lung02, TROPION-Lung04 and NeoCOAST-2 were presented at the 2025 American Society of Clinical Oncology Annual Meeting. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate, ADC, discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN). In 42 patients receiving first-line doublet DATROWAY plus pembrolizumab, an objective response rate of 54.8% was observed. In 54 patients receiving first-line triplet DATROWAY plus pembrolizumab and platinum chemotherapy, an ORR of 55.6% was observed. This analysis included patients enrolled during the dose escalation phase of the trial, where 4.8% and 40.7% of patients treated with the doublet and triplet regimens, respectively, received DATROWAY at a dose of 4 mg/kg versus 6 mg/kg. First results from cohort 5 of the TROPION-Lung04 phase 1b trial, presented during a poster session on Saturday, May 31, showed DATROWAY plus AstraZeneca's PD-1/TIGIT bispecific antibody rilvegostomig as a first-line treatment demonstrated an ORR of 57.5%, including one complete response and 22 partial responses in 40 patients with advanced or metastatic NSCLC. A disease control rate of 95% was seen. Final results from Arm 4 of the NeoCOAST-2 phase 2 platform trial evaluating neoadjuvant DATROWAY plus AstraZeneca's anti-PD-L1 therapy IMFINZI and single-agent platinum chemotherapy were presented during a poster session on Saturday, May 31 and showed the combination demonstrated a pathologic complete response rate of 35.2%

Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance
Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance

Business Insider

time5 hours ago

  • Business Insider

Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance

Arvinas (ARVN) and Pfizer (PFE) announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer, MBC, whose disease progressed following prior treatment with cyclin-dependent kinase, CDK, 4/6 inhibitors and endocrine therapy. These data, which were highlighted in the American Society of Clinical Oncology press briefing and selected for Best of ASCO, will be presented today in a late-breaking oral presentation and have been simultaneously published in the New England Journal of Medicine. In the trial, vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, PFS, among patients with an estrogen receptor 1, ESR1, mutation, reducing the risk of disease progression or death by 43% compared to fulvestrant. The median PFS, as assessed by blinded independent central review, BICR, was 5.0 months with vepdegestrant versus 2.1 months with fulvestrant. Investigator-assessed PFS was consistent with the BICR-assessed PFS. In patients with ESR1 mutations, vepdegestrant demonstrated a consistent PFS benefit over fulvestrant across all pre-specified subgroups. The trial did not reach statistical significance in improvement in PFS in the intent-to-treat population, with a median PFS of 3.7 months for vepdegestrant versus 3.6 for fulvestrant.

AstraZeneca announces results from MATTERHORN Phase III trial of IMFINZI
AstraZeneca announces results from MATTERHORN Phase III trial of IMFINZI

Business Insider

time5 hours ago

  • Business Insider

AstraZeneca announces results from MATTERHORN Phase III trial of IMFINZI

Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca's (AZN) IMFINZI in combination with standard-of-care FLOT chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival, EFS, versus chemotherapy alone. Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction, GEJ, cancers. In a planned interim analysis, patients treated with the IMFINZI-based perioperative regimen showed a 29% reduction in the risk of disease progression, recurrence or death versus chemotherapy alone. Estimated median EFS was not yet reached for the IMFINZI arm versus 32.8 months for the comparator arm. For the secondary endpoint of overall survival, a strong trend was observed in favor of the IMFINZI-based perioperative regimen. The trial will continue to follow OS, which will be formally assessed at the final analysis. Confident Investing Starts Here:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store